Bali Muralidhar's most recent trade in Spruce Biosciences Inc was a trade of 30,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Spruce Biosciences Inc | Bali Muralidhar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Spruce Biosciences Inc | Bali Muralidhar | Director | 22 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | ||
| Reneo Pharmaceuticals Inc | Bali Muralidhar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Spruce Biosciences Inc | Bali Muralidhar | Director | 25 May 2023 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | ||
| Exicure Inc | Bali Muralidhar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2022 | 50,000 | 50,000 | - | - | Employee Stock Option (right to buy) | |
| Reneo Pharmaceuticals Inc | Bali Muralidhar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 17,500 | 17,500 | - | - | Stock Option (right to buy) | |
| Spruce Biosciences Inc | Bali Muralidhar | Director | 25 May 2022 | 22,500 | 22,500 | - | - | Stock Option (Right to Buy) | ||
| Exicure Inc | Bali Muralidhar | Director | Purchase of securities on an exchange or from another person at price $ 0.19 per share. | 19 May 2022 | 1,472,126 | 8,449,126 (9%) | 1% | 0.2 | 285,151 | Common Stock |